Suramin inhibits the CD40-CD154 costimulatory interaction: A possible mechanism for immunosuppressive effects

Biochemical Pharmacology

Volumn 77, Issue 7, 2009, Pages 1236-1245

  Margolles Clark, Emilio ^a   Jacques Silva, M Caroline ^a   Ganesan, Lakshmi ^a   Umland, Oliver ^a   Kenyon, Norma S ^a   Ricordi, Camillo ^a   Berggren, Per Olof ^a,b   Buchwald, Peter ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

CD40 ligand; Costimulation; Immunosuppression; Protein protein interaction; Suramin

Indexed keywords

ADENOSINE TRIPHOSPHATE; B7 ANTIGEN; BENZAMIDE DERIVATIVE; CD40 ANTIGEN; CD40 LIGAND; CD86 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 6; INTERLEUKIN 8; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PURINERGIC P2 RECEPTOR; SURAMIN; URIDINE TRIPHOSPHATE;

ANTIGEN ANTIBODY COMPLEX; ARTICLE; B LYMPHOCYTE; CELL PROLIFERATION; CHEMICAL INTERACTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG STRUCTURE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INHIBITION KINETICS; ONCHOCERCIASIS; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN PROTEIN INTERACTION; T LYMPHOCYTE ACTIVATION; TRYPANOSOMIASIS;

ANIMALS; ANTIGENS, CD40; CD40 LIGAND; CELL PROLIFERATION; CELLS, CULTURED; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MICE; PROTEIN BINDING; SURAMIN;

EID: 61449238962     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.01.001     Document Type: Article

References (45)

1. Larsen C.P., Knechtle S.J., Adams A., Pearson T., and Kirk A.D. A new look at blockade of T-cell costimulation: a therapeutic strategy for long-term maintenance immunosuppression. Am J Transplant 6 (2006) 876-883
2. Vincenti F., and Luggen M. T cell costimulation: a rational target in the therapeutic armamentarium for autoimmune diseases and transplantation. Annu Rev Med 58 (2007) 347-358
3. Grewal I.S., and Flavell R.A. The role of CD40 ligand in costimulation and T-cell activation. Immunol Rev 153 (1996) 85-106
4. Schönbeck U., and Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 58 (2001) 4-43
5. Grewal I.S., and Flavell R.A. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 16 (1998) 111-135
6. Quezada S.A., Jarvinen L.Z., Lind E.F., and Noelle R.J. CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol 22 (2004) 307-328
7. Kenyon N.S., Chatzipetrou M., Masetti M., Ranuncoli A., Oliveira M., Wagner J.L., et al. Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. Proc Natl Acad Sci USA 96 (1999) 8132-8137
8. Barbé-Tuana F.M., Klein D., Ichii H., Berman D.M., Coffey L., Kenyon N.S., et al. CD40-CD40 ligand interaction activates proinflammatory pathways in pancreatic islets. Diabetes 55 (2006) 2437-2445
9. Ralevic V., and Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev 50 (1998) 413-492
10. Voogd T.E., Vansterkenburg E.L., Wilting J., and Janssen L.H. Recent research on the biological activity of suramin. Pharmacol Rev 45 (1993) 177-203
11. Stein C.A. Suramin: a novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res 53 (1993) 2239-2248
12. Cheson B.D., Levine A.M., Mildvan D., Kaplan L.D., Wolfe P., Rios A., et al. Suramin therapy in AIDS and related disorders. Report of the US Suramin Working Group. J Am Med Assoc 258 (1987) 1347-1351
13. Kaur M., Reed E., Sartor O., Dahut W., and Figg W.D. Suramin's development: what did we learn?. Invest New Drugs 20 (2002) 209-219
14. Cole D.J., Ettinghausen S.E., Pass H.I., Danforth D.N., Linehan M.W., Myers C.W., et al. Postoperative complications in patients receiving suramin therapy. Surgery 116 (1994) 90-95
15. Spigelman Z., Dowers A., Kennedy S., DiSorbo D., O'Brien M., Barr R., et al. Antiproliferative effects of suramin on lymphoid cells. Cancer Res 47 (1987) 4694-4698
16. Mills G.B., Zhang N., May C., Hill M., and Chung A. Suramin prevents binding of interleukin 2 to its cell surface receptor: a possible mechanism for immunosuppression. Cancer Res 50 (1990) 3036-3042
17. Czernin S., Gessl A., Wilfing A., Holter W., Trieb K., Waldhausl W., et al. Suramin affects human peripheral blood mononuclear cells in vitro: inhibition of T cell growth and modulation of cytokine secretion. Int Arch Allergy Immunol 101 (1993) 240-246
18. Schiller C., Spittler A., Willheim M., Szepfalusi Z., Agis H., Koller M., et al. Influence of suramin on the expression of Fc receptors and other markers on human monocytes and U937 cells, and on their phagocytic properties. Immunology 81 (1994) 598-604
19. Shenoy M., MacPherson B., and Christadoss P. Suramin inhibits the mixed lymphocyte reaction by suppressing lymphokine production. J Clin Immunol 12 (1992) 122-129
20. Zheng Z, Carter MB, Liao Y, Sun L, Kirkovsky L, Mrose S, et al., inventors; Biogen, Inc., assignee. Novel CD40:CD154 binding interruptor compounds and use thereof to treat immunological complications. US patent 7,173,046 B2. 2007 [February 6, 2007].
21. Boutonnat J., Barbier M., Muirhead K., Mousseau M., Ronot X., and Seigneurin D. Optimized fluorescent probe combinations for evaluation of proliferation and necrosis in anthracycline-treated leukaemic cell lines. Cell Prolif 32 (1999) 203-213
22. Gordon K.M., Duckett L., Daul B., and Petrie H.T. A simple method for detecting up to five immunofluorescent parameters together with DNA staining for cell cycle or viability on a benchtop flow cytometer. J Immunol Methods 275 (2003) 113-121
23. Ricordi C., Lacy P.E., Finke E.H., Olack B.J., and Scharp D.W. Automated method for isolation of human pancreatic islets. Diabetes 37 (1988) 413-420
24. Mancini F., Toro C.M., Mabilia M., Giannangeli M., Pinza M., and Milanese C. Inhibition of tumor necrosis factor-alpha (TNF-alpha)/TNF-alpha receptor binding by structural analogues of suramin. Biochem Pharmacol 58 (1999) 851-859
25. Bondada S., Troyer A., and Chelvarajan R.L. Early events in B lymphocyte activation. Curr Protoc Immunol (2003) [Chapter 3:Unit 3, 9]
26. Bajorath J. Detailed comparison of two molecular models of the human CD40 ligand with an X-ray structure and critical assessment of model-based mutagenesis and residue mapping studies. J Biol Chem 273 (1998) 24603-24609
27. Alzani R., Corti A., Grazioli L., Cozzi E., Ghezzi P., and Marcucci F. Suramin induces deoligomerization of human tumor necrosis factor α. J Biol Chem 268 (1993) 12526-12529
28. 3-symmetric peptide scaffolds are functional mimetics of trimeric CD40L. Nat Chem Biol 1 (2005) 377-382
29. Allen S.D., Rawale S.V., Whitacre C.C., and Kaumaya P.T. Therapeutic peptidomimetic strategies for autoimmune diseases: costimulation blockade. J Pept Res 65 (2005) 591-604
30. Deambrosis I., Lamorte S., Giaretta F., Tei L., Biancone L., Bussolati B., et al. Inhibition of CD40-CD154 costimulatory pathway by a cyclic peptide targeting CD154. J Mol Med 87 (2009) 181-197
31. Kitagawa M., Goto D., Mamura M., Matsumoto I., Ito S., Tsutsumi A., et al. Identification of three novel peptides that inhibit CD40-CD154 interaction. Mod Rheumatol 15 (2005) 423-426
32. Lutgens E., Gorelik L., Daemen M.J., de Muinck E.D., Grewal I.S., Koteliansky V.E., et al. Requirement for CD154 in the progression of atherosclerosis. Nat Med 5 (1999) 1313-1316
33. Vishnevetsky D., Kiyanista V.A., and Gandhi P.J. CD40 ligand: a novel target in the fight against cardiovascular disease. Ann Pharmacother 38 (2004) 1500-1508
34. Chakrabarti S., Blair P., and Freedman J.E. CD40-40L signaling in vascular inflammation. J Biol Chem 282 (2007) 18307-18317
35. Danese S., Scaldaferri F., Vetrano S., Stefanelli T., Graziani C., Repici A., et al. Critical role of the CD40 CD40-ligand pathway in regulating mucosal inflammation-driven angiogenesis in inflammatory bowel disease. Gut 56 (2007) 1248-1256
36. Zirlik A., Maier C., Gerdes N., MacFarlane L., Soosairajah J., Bavendiek U., et al. CD40 ligand mediates inflammation independently of CD40 by interaction with Mac-1. Circulation 115 (2007) 1571-1580
37. Goto T., Takeuchi S., Miura K., Ohshima S., Mikami K., Yoneyama K., et al. Suramin prevents fulminant hepatic failure resulting in reduction of lethality through the suppression of NF-κB activity. Cytokine 33 (2006) 28-35
38. Motta I., Brandely M., Truffa-Bachi P., Hurtrel B., and Lagrange P. Effects of suramin on the immune responses to sheep red blood cells in mice. II. In vitro studies. Cell Immunol 93 (1985) 292-302
39. Shiono T., Kodama M., Hanawa H., Fuse K., Yamamoto T., and Aizawa Y. Suppression of myocardial inflammation using suramin, a growth factor blocker. Circ J 66 (2002) 385-389
40. Grossman S.A., Phuphanich S., Lesser G., Rozental J., Grochow L.B., Fisher J., et al. Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade gliomas. J Clin Oncol 19 (2001) 3260-3266
41. Eichhorst S.T., Krueger A., Müerköster S., Fas S.C., Golks A., Gruetzner U., et al. Suramin inhibits death receptor-induced apoptosis in vitro and fulminant apoptotic liver damage in mice. Nat Med 10 (2004) 602-609
42. Freissmuth M., Waldhoer M., Bofill-Cardona E., and Nanoff C. G protein antagonists. Trends Pharmacol Sci 20 (1999) 237-245
43. Zhang Y.L., Keng Y.F., Zhao Y., Wu L., and Zhang Z.Y. Suramin is an active site-directed, reversible, and tight-binding inhibitor of protein-tyrosine phosphatases. J Biol Chem 273 (1998) 12281-12287
44. Chung W.C., and Kermode J.C. Suramin disrupts receptor-G protein coupling by blocking association of G protein α and βγ subunits. J Pharmacol Exp Ther 313 (2005) 191-198
45. Denkinger M., Shive C.L., Pantenburg B., and Forsthuber T.G. Suramin has adjuvant properties and promotes expansion of antigen-specific Th1 and Th2 cells in vivo. Int Immunopharmacol 4 (2004) 15-24